You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 10,369,161

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,369,161

Title:	Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
Abstract:	Disclosed are methods of administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient.
Inventor(s):	DeLuca; Hector F. (Deerfield, WI), Plum; Lori A. (Arena, WI), Clagett-Dame; Margaret (Deerfield, WI)
Assignee:	Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:	14/710,744
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,369,161
Patent Claims:	1. A method of reducing serum parathyroid hormone levels in a subject having primary hyperparathyroidism and exhibiting elevated serum parathyroid hormone levels, the method comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 or a pharmaceutically acceptable salt thereof to the subject wherein the serum parathyroid hormone levels in the subject are reduced without inducing hypercalcemia in the subject. 2. The method of claim 1, wherein the therapeutically effective amount ranges from about 0.5 ng/kg to about 20 ng/kg. 3. The method of claim 1, wherein the therapeutically effective amount ranges from about 1.0 ng/kg to about 10 ng/kg. 4. The method of claim 1, wherein the subject is administered the therapeutically effective amount daily. 5. The method of claim 1, wherein the subject is administered the therapeutically effective amount three times per week. 6. The method of claim 1, wherein prior to treatment the subject has a serum parathyroid hormone (PTH) level of greater than about 55 pg/ml. 7. The method of claim 1, wherein after treatment the subject has a serum parathyroid hormone (PTH) level that dose not exceed 55 pg/ml. 8. The method of claim 1, wherein the 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 is formulated in an oral, topical, transdermal, parenteral, injection or infusion dosage form.

Details for Patent 10,369,161

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2034-12-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.